Solar 18 Corporation (SLRN)
| Market Cap | 227.15M |
| Revenue (ttm) | 250.00M |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 2.270 |
| Day's Range | n/a |
| 52-Week Range | 1.845 - 7.250 |
| Beta | 1.09 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2025 |
About SLRN
Solar 18 Corporation develops, designs, and markets alternative energy & processes. The company was formerly known as Atlan International Holdings Corp. and changed the name to Solar 18 Corporation in May, 2008. The company was founded in 2001 and is based in New York, New York.
Financial Performance
Financial StatementsNews
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in...
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS ANGELES, May 01, 2025 (GLOBE NEWSWIRE) -- ACELYRIN,...
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acelyrin, Inc. (...
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines ...
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC...
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma com...
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.
NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by ACELYRIN, INC. (NASDAQ: SLRN) and its board of directors concerning the proposed acquisi...
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines ...
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
LOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
Lonigutamab is the first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease (TED) patients
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
Completed enrollment in izokibep Phase 3 trial in hidradenitis suppurativa and enrollment completion in Phase 2b/3 trial in uveitis expected this month; top line data for both trials now expected by e...
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines ...
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance and is expected to be the first of two registrational trials in psoriatic arthritis
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
Dose ordered and robust HiSCRs were rapidly demonstrated with about a third of patients achieving HiSCR100, or resolution of abscesses and nodules, by week 16 and through week 32
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
Highly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies
ACELYRIN INVESTOR DEADLINE APPROACHING
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options If you suffered losses exceedi...